Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer
September 20, 2021 09:12 ET
|
Trigone Pharma, Ltd.
RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (“Trigone”), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the...
Trigone Pharma Announces the Initiation of a Phase 2 Clinical Trial of TRG-100 in Patients with Interstitial Cystitis/Bladder Pain Syndrome
August 13, 2021 08:00 ET
|
Trigone Pharma, Ltd.
RAANANA, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma Ltd. a leader in the field of urological diseases, today announced the initiation of a Phase 2 study of TRG-100 in patients with...
Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis / Bladder Pain Syndrome at the Upcoming American Urological Association Conference (AUA) in September 2021
July 22, 2021 11:11 ET
|
Trigone Pharma, Ltd.
RAANANA, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma Ltd., a privately owned biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...